Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Tabrecta
Capmatinib is a kinase inhibitor specifically targeting mesenchymal-epithelial transition factor (MET) exon 14 skipping mutations. It is used to treat non-small cell lung cancer (NSCLC) in patients whose tumors exhibit these specific mutations. This targeted therapy works by disrupting MET signaling pathways crucial for tumor growth and survival. Capmatinib is an oral medication, typically administered as a tablet.
Capmatinib treats non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations.
Outcome:
Increased capmatinib levels
Mechanism:
Reduced metabolism
Outcome:
Increased capmatinib levels
Mechanism:
Reduced metabolism
Outcome:
Potential slight increase in capmatinib levels
Mechanism:
Minimal impact on metabolism
Most likely new formulation: Extended-release formulation (2026, 80% confidence)
Based on current clinical trial data and usage trends, there is a 70% likelihood of capmatinib expanding its approved indications to other MET-driven cancers within the next 5 years.
Kinase Inhibitor, Antineoplastic
Pyrrolopyrimidine derivative